Indeed, mutations of human glucokinase are seen in a specific subtype of type 2 diabetes (GCK-MODY), which results in a chronic, mild increase in blood glucose levels in part due to decreased glucokinase activity in the pancreas and the associated lower insulin release (Ashcroft et al. 2023). This evidence concerns the gene GCK and type 2 diabetes mellitus.